Silence Therapeutics (SLN) said Monday that Chief Executive and President Craig Tooman "agreed by mutual consent" to terminate his employment with the company, effective Dec. 14.
Board Chair Iain Ross will lead Silence on an interim basis, effective immediately, the company said.
Silence shares were down 2% in early trading Monday.
Price: 6.20, Change: -0.13, Percent Change: -1.98
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments